Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,000 questions in 69 reviews · Urology
current versionsNo studies 196 · 19.6%Ungraded 33 · 3.3%Very low 198 · 19.8%Low 354 · 35.4%Moderate 206 · 20.6%High 13 · 1.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent) Progression‐free survival(absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.45 [1.19, 1.76] | 1 study · 861 participants | Moderate |
Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent) Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.9 [1.36, 2.65] | 1 study · 861 participants | Moderate |
Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 0.9 [0.81, 1.02] | 1 study · 854 participants | Low |
Sunitinib vs pembrolizumab + axitinib (targeted agent versus immunotherapy + targeted agent) Health‐related quality of life4 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent) Progression‐free survival(absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.18 [1.02, 1.36] | 2 studies · 1117 participants | Low |
Sorafenib vs sunitinib (targeted agent versus targeted agent) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 0.99 [0.85, 1.14] | 1 study · 353 participants | Very low |
Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent) Overall survival(absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.99 [0.73, 1.33] | 2 studies · 1117 participants | Very low |
Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.22 [1, 1.49] | 2 studies · 1098 participants | Very low |
Sunitinib vs atezolizumab + bevacizumab (targeted agent versus immunotherapy + targeted agent) Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | 2 studies · 691 participants | Low |
Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.95 [0.7, 1.3] | 1 study · 339 participants | Very low |
Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent) Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.75 [0.54, 1.04] | 1 study · 339 participants | Low |
Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 0.74 [0.59, 0.95] | 1 study · 334 participants | Low |
Sunitinib vs IMA901 + sunitinib (targeted agent versus tumour vaccine + targeted agent) Health‐related quality of life6 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Sunitinib vs interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 6 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.54 [0.45, 0.64] | 1 study · 750 participants | Moderate |
Sunitinib vs interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.82 [0.67, 1] | 1 study · 750 participants | Low |
Sunitinib vs interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) Serious adverse events (Grade 3 or 4)assessed as: CTCAE v3.0 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.75 [1.43, 2.16] | 1 study · 735 participants | Moderate |
Sorafenib vs sunitinib (targeted agent versus targeted agent) Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Sunitinib vs interferon‐α (IFN‐α) (targeted agent versus classic immunotherapy) Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | 1 study · 544 participants | Moderate |
Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.74 [0.6, 0.91] | 1 study · 416 participants | Low |
Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy) Overall survival survival (absolute effect size estimates based on survival rate at 12 months ) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.78 [0.63, 0.97] | 1 study · 416 participants | Moderate |
Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 0.86 [0.76, 0.97] | 1 study · 408 participants | Low |
Temsirolimus vs IFN‐α (targeted agent versus classic immunotherapy) Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | 1 study · 401 participants | Low |
Sunitinib vs atezolizumab (targeted therapy versus immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.84 [0.58, 1.22] | 1 study · 204 participants | Very low |
Sunitinib vs atezolizumab (targeted therapy versus immunotherapy) Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.94 [0.58, 1.54] | 1 study · 204 participants | Very low |
Sunitinib vs atezolizumab (targeted therapy versus immunotherapy) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.73 [1.32, 2.27] | 1 study · 203 participants | Moderate |
Sunitinib vs atezolizumab (targeted therapy versus immunotherapy) Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | 1 study · 157 participants | Low |
Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.68 [0.6, 0.77] | 2 studies · 1381 participants | Moderate |
Pazopanib vs sunitinib (targeted agent versus targeted agent) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.05 [0.9, 1.23] | 1 study · 1110 participants | Low |
Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy) Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.88 [0.79, 0.99] | 2 studies · 1381 participants | Low |
Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.31 [1.2, 1.42] | 2 studies · 1356 participants | Moderate |
Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy) Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Temsirolimus + IFN‐α vs IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.76 [0.62, 0.93] | 1 study · 417 participants | Low |
Temsirolimus + IFN‐α vs IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy) Overall survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.93 [0.75, 1.15] | 1 study · 417 participants | Low |
Temsirolimus + IFN‐α vs IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.12 [1.02, 1.22] | 1 study · 408 participants | Low |
Temsirolimus + IFN‐α vs IFN‐α (targeted agent + classic immunotherapy versus classic immunotherapy) Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | 1 study · 394 participants | Low |
Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.1 [0.9, 1.34] | 1 study · 791 participants | Low |
Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.08 [0.9, 1.3] | 1 study · 791 participants | Moderate |
Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.05 [0.98, 1.13] | 1 study · 784 participants | Low |
Pazopanib vs sunitinib (targeted agent versus targeted agent) Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.92 [0.8, 1.06] | 1 study · 1110 participants | Low |
Temsirolimus + bevacizumab vs bevacizumab + IFN‐α (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (any cell type [80% clear cell]) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Everolimus + bevacizumab vs IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 18 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.91 [0.69, 1.2] | 1 study · 365 participants | Very low |
Everolimus + bevacizumab vs IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.01 [0.75, 1.36] | 1 study · 365 participants | Very low |
Everolimus + bevacizumab vs IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.06 [0.95, 1.18] | 1 study · 361 participants | Low |
Everolimus + bevacizumab vs IFN α‐2a + bevacizumab (targeted agent + targeted agent versus targeted agent + classic immunotherapy) Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | NR | No studies |
Sunitinib vs nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy) Progression‐free survival (absolute effect size estimates based on survival rate at 30 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only. Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.3 [1.11, 1.52] | 1 study · 847 participants | Low |
Sunitinib vs nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy) Overall survival (absolute effect size estimates based on survival rate at 30 months) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only. Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 1.52 [1.23, 1.89] | 1 study · 847 participants | High |
Sunitinib vs nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only. Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.37 [1.22, 1.53] | 1 study · 1082 participants | Moderate |
Sunitinib vs nivolumab + ipilimumab (targeted agent versus combinations of immunotherapy) Health‐related quality of life · Treatment‐naïve metastatic renal cell carcinoma (clear cell type); IMDC intermediate, poor risk patients only. Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | no estimate extracted | 1 study · 460 participants | Moderate |
Pazopanib vs placebo (targeted agent versus placebo) Progression‐free survival (absolute effect size estimates based on survival rate at 12 months) · Previous treated and treatment‐naïve (54%) metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | HR 0.46 [0.34, 0.62] | 1 study · 435 participants | High |
Pazopanib vs sunitinib (targeted agent versus targeted agent) Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane | RR 1.01 [0.94, 1.09] | 1 study · 1102 participants | Low |